Inhibitory activity of test compounds against HIV-1-infected C8166 cultures or HIV-1-exposed Raji/DC-SIGN cells cocultivated with uninfected C8166 cells
Data are presented as the mean ± S.D. of two to three independent experiments. The following formula was used for the calculation of the S.D.: 
.
Test Compound | EC50 | Ratio EC50 Condition C/A | ||||
|---|---|---|---|---|---|---|
| Condition Aa | Condition Bb | Condition Cc | ||||
| μg / ml | ||||||
| HHA | 13 ± 6.5 | >20 | 32 ± 7.5 | 2.4 | ||
| GNA | 20 ± 0.0 | >20 | 42 ± 2.5 | 2.1 | ||
| NPA | 0.90 ± 0.1 | 3.1 ± 0.9 | 0.9 ± 0.3 | 1.0 | ||
| CA | 0.85 ± 0.05 | 7.0 ± 3.0 | 1.5 ± 0.5 | 1.7 | ||
| CV-N | 0.007 ± 0.003 | 0.35 ± 0.15 | 0.04 ± 0.0 | 5.7 | ||
| UDA | 25 ± 15 | 45 ± 5.0 | 30 ± 10 | 1.2 | ||
| mAb 2G12 | 2.0 ± 0.0 | 22 ± 2.5 | 0.9 ± 0.1 | 0.45 | ||
| mAb F105 | 1.1 ± 0.1 | ≫1 | 5 ± 0.0 | 4.5 | ||
| mAb 9205 | 0.01 ± 0.0 | 0.045 ± 0.005 | 0.005 ± 0.001 | 0.60 | ||
| Enfuvirtide | 0.75 ± 0.05 | 2.7 ± 1.2 | >25 | >33 | ||
| AMD3100 | 0.035 ± 0.015 | 0.85 ± 0.65 | >50 | >1428 | ||
| Maraviroc | >1.0 | >1.0 | >1 | |||
| CADA | 2.1 ± 0.1 | 1.1 ± 0.35 | >50 | >24 | ||
| DS-5000 | 0.8 ± 0.0 | 4.8 ± 3.2 | >250 | >312 | ||
| PVAS | 1.4 ± 0.6 | 2.2 ± 0.25 | ≥250 | ≥178 | ||
| PRO-2000 | 0.3 ± 0.1 | 6.0 ± 4.0 | ≥25 | ≥83 | ||
-
↵ a 50% effective concentration required to prevent syncytia formation in HIV-1(IIIB)-infected C8166 cell cultures at day 3 after infection.
-
↵ b 50% effective concentration required to prevent syncytia formation in HIV-1(IIIB)-exposed Raji/DC-SIGN cell cultures that were cocultivated with uninfected C8166 cells in the continuing presence of different concentrations of the test compounds.
-
↵ c 50% effective concentration required to prevent syncytia formation in test compound-pre-exposed HIV-1(IIIB)-infected Raji/DC-SIGN cell cultures, cocultivated with uninfected C8166 cells in the absence of the test compounds.